Taragarestrant
Taragarestrant is an orally bioavailable selective estrogen receptor degrader (SERD) developed by Inventis Bio for the treatment of estrogen receptor-positive (ER+) breast cancer.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Taragarestrant is an orally bioavailable selective estrogen receptor degrader (SERD) developed by Inventis Bio for the treatment of estrogen receptor-positive (ER+) breast cancer. Structurally similar to AZD9496, taragarestrant has demonstrated potent efficacy across multiple breast cancer cell lines expressing ER and related xenograft models.
In preclinical studies, taragarestrant exhibited anti-tumor activity, warranting further clinical investigation. A phase I study (NCT03471663) evaluated taragarestrant in females with ER+/HER2- advanced or metastatic breast cancer, both as monotherapy and in combination with the CDK4/6 inhibitor palbociclib.
A phase III clinical trial has been initiated in China in patients with ER+/HER2- advanced or metastatic breast cancer.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1347514996 under CC BY-SA 4.0; modifications have been made.